New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Cardio3 BioSciences
- rue Edouard Belin 12
- Mont-Saint-Guibert , 1435
Cardio3 BioSciences is a biopharmaceutical company involved in the discovery, development, and commercialization of regenerative and protective therapies for cardiovascular diseases.The aim of these therapies is to protect the heart during myocardial injury, reduce the volume of the scar and reconstruct damaged heart tissue. The company’s product candidates and research programs are based on the proprietary Cardiopoiesis technology platform, which is based on fundamental research conducted at Mayo Clinic.